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NANOTUBES AS MITOCHONDRIAL 
UNCOUPLERS 
CROSS-REFERENCE TO RELATED 
APPLICATION 
This application claims priority under 35 U.S.C. §119 to 
US. Provisional Application No. 60/678,355 entitled 
NANOTUBES AS MITOCHONDRIAL UNCOUPLERS, 
?led May 6, 2005, the entire content of Which is hereby 
incorporated by reference. 
FIELD OF THE INVENTION 
The present invention relates to nanotubes as mitochon 
drial uncouplers. The present invention provides methods of 
mitochondrial uncoupling as Well as methods of treating dis 
ease conditions and increasing Weight loss by administering 
the nanotubes. 
BACKGROUND 
It is knoWn that mitochondria control metabolism in indi 
vidual cells by burning sugars and fats. Mitochondria produce 
a membrane potential of about 200 mV across their inner 
membrane by the active translocation of protons from the 
matrix of the mitochondria (the inside) into the inner mem 
brane space (mitochondria have an inner an outer membrane 
as illustrated in FIG. 2). The translocation of protons from the 
matrix is due to the activity of the electron transport system, 
Which takes electrons from a high energy state to a loWer 
energy resulting in the reduction of oxygen to Water, hence 
the term mitochondrial respiration since oxygen is consumed 
by this process. The energy released as electrons are taken 
from a high energy state to a loWer energy state is used by this 
electron transport system to translocate (i.e., pump) the pro 
tons from the matrix to the inner membrane space resulting in 
a separation of charge (i.e., membrane potential) as Well as a 
pH gradient across the inner membrane due to the movement 
of these protons. 
The mitochondrial membrane potential is then “coupled” 
to the controlled How of protons back into the matrix through 
the ATP synthase Which uses this How to phosphorylate 
adenosine diphosphate (“ADP”) to ATP. 
Chemical uncouplers of mitochondria have been used to 
increase the bodies basal metabolism to encourage Weight 
loss. HoWever, chemical uncouplers are readily toxic, as they 
are di?icult to control. Uncontrolled uncoupling of mitochon 
dria (i.e., dropping the mitochondrial membrane potential 
beloW about 100 mV) causes an inability to produce cellular 
ATP, Which eventually leads to death. 
Therefore, there is a need for safe, controllable, mitochon 
drial uncouplers that can separeate the mitochondria respira 
tion from the production of ATP, and thus safely produce the 
desired effect, Without harming the individual. 
SUMMARY OF THE INVENTION 
The present invention provides nanotubes Which safely 
uncouple mitochondria, as the nanotubes can be prepared 
such that the proton channel automatically shuts doWn When 
an unsafe potential is reached. 
The template method of forming nanotubes in one embodi 
ment alloWs control of the dimensions of the nanotubes such 
that the nanotubes can be designed to have any desired dimen 
sions as speci?ed. By alloWing manipulation of siZe, particu 
larly the inner diameter of the nanotubes (as explained 
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above), these nanotubes alloW speci?c conductance (i.e., 
uncoupling threshold and resistance to proton How) of the 
nanotubes. The template method further alloWs lining or coat 
ing the inside and outside of the nanotubes With any desired 
materials. 
Template synthesis of nanotubes generally involves the 
deposition of materials (e.g., gold, alumina, silica etc.) into 
the cylindrical pores of mass-produced track-etched mem 
branes (e.g., Coming Corp; Osmonics). Once the nanotubes 
are formed Within the membrane pores, the membrane can be 
dissolved and the nanotubes can be captured via ?ltration. By 
altering the conditions during preparation (e.g., reducing the 
plating time When using the electroless plating method for 
creating gold nanotubes increases the inner diameter of the 
nanotube accordingly) the internal diameter, length and con 
tents of the nanotube can be controlled as speci?ed. 
According to another embodiment, nanotubes made of 
metals and/or polymers are used to safely uncouple mito 
chondria, raise metabolism, and promote Weight loss. 
According to another embodiment, the nanotubes have a 
length of about 8-12 nm and a diameter of about 1-3 nm, 
Wherein the nanotubes can cross cell membranes substan 
tially easily, and Wherein the mitochondria have a length of 
about 1000-5000 nm and the bilipid membrane of the mito 
chondria is about 8-10 nm thick. 
According to a further embodiment, the nanotubes can be 
active only in the mitochondria. This is due to the fact that the 
nanotubes only act as proton channels When a signi?cantly 
high potential is applied (about 130-150 mV), Which is only 
found across the mitochondrial inner membrane in mammal 
cells. 
In a further embodiment, the interior surface of the non 
carbon based nanotubes can be doped With compounds of 
speci?c pKa such that the non-carbon based nanotube shuts 
off When a speci?c pH is reached. This alloWs us to take 
advantage of the fact that mitochondria have a pH gradient 
across the inner membrane as a result of the pumping of 
protons from the matrix across the inner membrane via the 
electron transport system. 
In one embodiment, the nanotubes act as proton channels 
speci?cally in the mitochondria. The nanotubes acting as 
proton channels cause a reduction in mitochondrial mem 
brane potentials Which in turn increases basal metabolism, 
decreases reactive oxygen species (“ROS”), and decreases 
detrimental loading of Ca2+ into mitochondria. The reason for 
this is that all these parameters are a function of the membrane 
potential such that a high mitochondrial membrane potential 
sloWs doWn metabolism and increases ROS formation and the 
uptake of Ca2+ into mitochondria. 
The nanotubes conduct protons (i.e., open and uncouple 
mitochondria) only When a speci?c potential (i.e., breakover 
voltage) is reached. This causes a drop in the mitochondrial 
membrane potential that closes the nanotube proton channel, 
in effect making the nanotubes self-rectifying. Therefore, 
nanotubes can be designed to maintain a speci?c mitochon 
drial membrane potential that can signi?cantly increase 
metabolism Without the possibility of toxicity since the nano 
tubes Will not function (act as proton channels) at a mitochon 
drial membrane potential beloW the threshold for ATP pro 
duction. 
According to one embodiment, the dimensions of nano 
tubes and the materials they are made from are manipulated to 
accomplish safe mitochondrial uncoupling. For example, 
When the diameter of the nanotubes is decreased, a smaller 
diameter increases resistance and the conductance of protons 
through the nanotubes (uncouples the mitochondria electron 
transport from ATP production) only When the voltage 
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reaches threshold (the mitochondrial membrane potential). 
These nanotubes that are highly effective for Weight-loss and 
at the same time are substantially safe for use because they are 
self-rectifying. 
In one embodiment, nanotubes can offer a safe and effec 
tive treatment for obesity and Weight management by increas 
ing basal metabolism by increasing mitochondrial respira 
tion. 
In another embodiment a method of uncoupling mitochon 
dria in a subject comprising administering nanotubes to the 
subject in a therapeutically effective amount, Wherein the 
nanotubes are self-rectifying is disclosed. 
The nanotubes can be coated With a pKa reducing com 
pound. The subject can be a mammal. The nanotubes have an 
inner diameter suitable for uncoupling mitochondria. The 
nanotubes have an inner diameter Which alloWs the nanotubes 
to self-rectify. 
The nanotubes comprise metals or polymers, Wherein the 
metal is gold or silver, and Wherein the polymers are natural 
polymers or synthetic polymers. The polymers are preferably 
selected from the group consisting of poly(vinyl alcohol), 
poly(esters), polyglycolide, polycaprolactone, poly(ethylene 
oxide), poly(butylene terephthalate), poly(hydroxyal 
kanoates), hydrogels, modi?ed poly(saccharides), starch, 
cellulose, chitosan and combinations thereof. 
In another embodiment, a method of decreasing reactive 
oxygen species and decreasing detrimental loading of Ca2+ 
into mitochondria of a subject comprising administering 
nanotubes to the subject in a therapeutically effective amount, 
Wherein the nanotubes are self-rectifying is disclosed. 
The subject can be a mammal. The nanotubes have an inner 
diameter designed for uncoupling mitochondria. The nano 
tubes have an inner diameter Which alloWs the nanotubes to 
self-rectify. The nanotubes comprise metals or polymers, 
Wherein the metal is gold or silver, and Wherein the polymers 
are natural polymers or synthetic polymers. The polymers are 
preferably selected from the group consisting of poly(vinyl 
alcohol), poly(esters), polyglycolide, polycaprolactone, poly 
(ethylene oxide), poly(butylene terephthalate), poly(hy 
droxyalkanoates), hydrogels, modi?ed poly(saccharides), 
starch, cellulose, and chitosan. 
In another embodiment, a method of reducing Weight in a 
subject comprising administering a therapeutically effective 
amount of nanotubes to the subject, Wherein the nanotubes 
are self-rectifying is disclosed. 
The subject can be a mammal. The nanotubes have an inner 
diameter designed for uncoupling mitochondria. The nano 
tubes have an inner diameter Which alloWs the nanotubes to 
self-rectify. The nanotubes comprise metals or polymers, 
Wherein the metal is gold or silver, and Wherein the polymers 
are natural polymers or synthetic polymers. The polymers are 
preferably selected from the group consisting of poly(vinyl 
alcohol), poly(esters), polyglycolide, polycaprolactone, poly 
(ethylene oxide), poly(butylene terephthalate), poly(hy 
droxyalkanoates), hydrogels, modi?ed poly(saccharides), 
starch, cellulose, and chitosan. 
In another embodiment, a method of treating cancer in an 
subject comprising administering a therapeutically effective 
amount of nanotubes to the subject, Wherein the nanotubes 
are self-rectifying is disclosed. 
The subject can be a mammal. The nanotubes have an inner 
diameter designed for uncoupling mitochondria. The nano 
tubes have an inner diameter Which alloWs the nanotubes to 
self-rectify. The nanotubes comprise metals or polymers, 
Wherein the metals are gold or silver, and Wherein the poly 
mers are natural polymers or synthetic polymers. The poly 
mers are preferably selected from the group consisting of 
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poly(vinyl alcohol), poly(esters), polyglycolide, polycapro 
lactone, poly(ethylene oxide), poly(butylene terephthalate), 
poly(hydroxyalkanoates), hydrogels, modi?ed poly(saccha 
rides), starch, cellulose, and chitosan. 
In another embodiment a method of reducing the effects of 
traumatic brain injury in an subject comprising administering 
a therapeutically effective amount of nanotubes to the subject, 
Wherein the nanotubes are self-rectifying is disclosed. 
The subject can be a mammal. The nanotubes have an inner 
diameter designed for uncoupling mitochondria. The nano 
tubes have an inner diameter Which alloWs the nanotubes to 
self-rectify. The nanotubes comprise metals or polymers, 
Wherein the metals are gold or silver, and Wherein the poly 
mers are natural polymers or synthetic polymers. The poly 
mers are preferably selected from the group consisting of 
poly(vinyl alcohol), poly(esters), polyglycolide, polycapro 
lactone, poly(ethylene oxide), poly(butylene terephthalate), 
poly(hydroxyalkanoates), hydrogels, modi?ed poly(saccha 
rides), starch, cellulose, and chitosan. 
In another embodiment, a method of reducing the effects of 
ageing in a subject comprising administering a therapeuti 
cally effective amount of nanotubes to the subject, Wherein 
the nanotubes are self-rectifying is disclosed. 
The subject can be a mammal. The nanotubes have an inner 
diameter designed for uncoupling mitochondria. The nano 
tubes have an inner diameter Which alloWs the nanotubes to 
self-rectify. The nanotubes comprise metals or polymers, 
Wherein the metals are gold or silver, and Wherein the poly 
mers are natural polymers or synthetic polymers. The poly 
mers are preferably selected from the group consisting of 
poly(vinyl alcohol), poly(esters), polyglycolide, polycapro 
lactone, poly(ethylene oxide), poly(butylene terephthalate), 
poly(hydroxyalkanoates), hydrogels, modi?ed poly(saccha 
rides), starch, cellulose, and chitosan. 
In another embodiment, a pharmaceutical composition is 
disclosed, Wherein the pharmaceutical composition com 
prises nanotubes in a pharmaceutically acceptable carrier, 
and Wherein the pharmaceutical composition is administered 
to an subject by (i) intravenous delivery, (ii) ingestion, (iii) 
particle bombardment via a gene gun, or (iv) patch or gel 
application to the dermis. 
In another embodiment a method of reducing the effects 
spinal cord injury in a subject comprising administering a 
therapeutically effective amount of nanotubes to the subject, 
Wherein the nanotubes are self-rectifying is disclosed. 
In another embodiment, a method of reducing the effects of 
stroke in a subject comprising administering a therapeutically 
effective amount of nanotubes into the subject, Wherein the 
nanotubes are self-rectifying is disclosed. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 shoWs tWo line graphs indicating that 2,4-DNP 
increases metabolism and Weight loss in a dose-dependent 
manner in humans. 
FIG. 2 shoWs bar graphs that illustrate mitochondrial 
uncoupling as a result of administering 2,4-DNP increases 
tissue sparing folloWing traumatic brain injury. 
FIG. 3 shoWs bar graphs that illustrate post-injury admin 
istration of 2,4-DNP increases tissue sparing folloWing spinal 
cord injury (“SCI”). 
FIG. 4 shoWs electron microscopy photomicrographs of 
isolated cortical mitochondrial folloWing the addition of 
nanotubes (24 hour+histidine) that Were made in the presence 
(left panel) or absence (right panel) of PEG. 
US 7,919,699 B2 
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FIG. 5 shows a higher magni?cation of isolated cortical 
mitochondrial following the addition of nanotubes (24 hour+ 
histidine) that Were made in the presence of PEG. 
FIG. 6 is a bar graph that shoWs that mitochondrial respi 
ration is increased as a function of nanotube plating time (the 
longer the plating the time the smaller the diameter of the 
nanotube) and/or the “doping” of the inside of the nanotube 
With compounds of speci?c pKas. 
FIG. 7 shoWs nanotubes manufactured by plating for 24 hrs 
and/or “doped” With histidine do not impair mitochondrial 
ATP production. 
FIG. 8 shoWs nanotubes manufactured by plating nano 
tubes for 24 hrs and/or doping them With histidine increase 
respirations less than nanotubes manufactured for shorter 
times. 
FIG. 9 shoWs that sequential additions of nanotubes results 
in a saturation point being reached due the self-rectifying 
nature of the nanotubes. 
FIG. 10 shoWs that nanotubes reduce mitochondrial mem 
brane potential Which explains their ability to increase respi 
ration, oxygen consumption and metabolism. 
FIG. 11 shoWs that nanotubes reduce reactive oxygen spe 
cies production in isolated mitochondria. 
FIG. 12 shoWs a line graph of days V. grams of Weight 
gained upon administering nanotubes compared to adminis 
tering vehicle controls over a period of seven days. 
FIG. 13 shoWs a line graph of days V. grams of Weight 
gained upon administering nanotubes compared to adminis 
tering vehicle controls over a period of 31 days. 
DETAILED DESCRIPTION OF THE INVENTION 
De?nitions 
In accordance With this detailed description, the folloWing 
abbreviations and de?nitions apply. It must be noted that as 
used herein, the singular forms “a”, “an”, and “the” include 
plural referents unless the context clearly dictates otherWise. 
Thus, for example, reference to “compounds” includes a plu 
rality of such compounds and reference to “the dosage” 
includes reference to one or more dosages and equivalents 
thereof knoWn to those skilled in the art, and so forth. 
The publications discussed herein are provided solely for 
their disclosure prior to the ?ling date of the present applica 
tion. Nothing herein is to be construed as an admission that 
the present invention is not entitled to antedate such publica 
tion by virtue of prior invention. Further, the dates of publi 
cation provided may be different from the actual publication 
dates, Which may need to be independently con?rmed. 
Unless otherWise stated, the folloWing terms used in the 
speci?cation and claims have the meanings given beloW: 
“Pharmaceutically acceptable carrier” means a carrier that 
is useful in preparing a pharmaceutical composition that is 
generally safe, non toxic and neither biologically nor other 
Wise undesirable, and includes a carrier that is acceptable for 
veterinary use as Well as human pharmaceutical use. “A phar 
maceutically acceptable carrier” as used in the speci?cation 
and claims includes both one, and more than one, such carrier. 
“Treating” or “treatment” of a disease includes: 
(1) preventing the disease, i.e., causing the clinical symptoms 
of the disease not to develop in a mammal that may be 
exposed to or predisposed to the disease but does not yet 
experience or display symptoms of the disease, 
(2) inhibiting the disease, i.e., arresting or reducing the devel 
opment of the disease or its clinical symptoms, or 
(3) relieving the disease, i.e., causing regression of the disease 
or its clinical symptoms. 
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A “therapeutically effective amount” or “pharmaceutically 
effective amount” means the amount of a compound that, 
When administered to a mammal, is su?icient to uncouple 
mitochondria, and/ or su?icient to decreasing reactive oxygen 
species and decreasing detrimental loading of Ca2+ into mito 
chondria. A “therapeutically effective amount” or “pharma 
ceutically effective amount” also means and amount su?i 
cient for treating a disease and su?icient to effect such 
treatment for the disease. The “therapeutically effective 
amount” Will vary depending on the compound, the disease 
and its severity and the age, Weight, etc., of the mammal to be 
treated. A “therapeutically effective amount” also may refer 
to an amount su?icient to cause Weight loss. 
“Pharmaceutically acceptable salt” refers to pharmaceuti 
cally acceptable salts of scopolamine Which salts are derived 
from a variety of organic and inorganic counter ions Well 
knoWn in the art and include, by Way of example only, 
sodium, potassium, calcium, magnesium, ammonium, tet 
raalkylammonium, and the like; and When the molecule con 
tains a basic functionality, salts of organic or inorganic acids, 
such as hydrochloride, hydrobromide, tartrate, mesylate, 
acetate, maleate, oxalate and the like. 
“Optional” or “optionally” means that the subsequently 
described event or circumstance may, but need not, occur, and 
that the description includes instances Where the event or 
circumstance occurs and instances in Which it does not. 
The term “individual” is a vertebrate, preferably a mam 
mal. Mammals include, but are not limited to, humans, 
rodents (i.e., mice, rats, and hamsters), farm animals, sport 
animals and pets. In a preferred embodiment, the individual is 
a mammal and more preferably, a human. 
As used herein, the term “introducing” means providing or 
administering to an individual. Methods of introducing nano 
tubes into individuals are Well knoWn to those of ordinary 
skill in the art and include, but are not limited to, injection, 
intravenous or parenteral administration. Single, multiple, 
continuous or intermittent administration can be effected. 
As used herein, the term “nanotube” includes structures 
formed from various materials using a generally knoWn tem 
plate method. Further, nanotubes include structures of vari 
ous shapes having dimensions smaller than about 1000 nm, 
preferably smaller than about 100 nm, more preferably 
smaller than about 50 nm, and most preferably smaller than 
about 20 nm. In a preferred embodiment, these nanostruc 
tures are holloW tube-like and/ or solid Wire-like structures. 
As used herein, the term “self-rectifying” refers to the 
ability of the nanotubes to stop acting as a proton channel 
once the mitochondrial membrane potential is loWered to a set 
threshold. 
Nanotubes 
The present invention relates to nanotubes used as mito 
chondrial uncouplers-in the body. Previous mitochondrial 
uncouplers, such as 2,4-DNP, are often toxic as they decrease 
and/or stop the production of ATP in the body. The nanotubes 
of the present invention act are safe, as they do not adversely 
affect production of ATP and utiliZe a different uncoupling 
mechanism than the mechanism of the chemical uncouplers. 
The presently disclosed nanotubes act as self-rectifying 
proton channels across the mitochondrial inner membrane. 
When the membrane potential reaches a certain point, the 
nanotubes shut off the proton How. This mechanism is similar 
to that of an electrical circuit, as the How across mitochondrial 
membranes folloWs the principles of Ohm’s laW. According 
to Ohm’s laW, V (voltage):I (current) R (resistance) (i.e., if 
one reduces R, I Will increase). In the case of mitochondria, 
the voltage is the separation of protons across the inner mem 
brane due to mitochondrial respiration (i.e., electron transport 
US 7,919,699 B2 
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system activity) and the current is the How of protons back 
across the inner membrane back into the matrix (i.e., How of 
protons through the ATP synthase or nanotubes). 
Under normal conditions, resistance (“R”) is set by the 
demand for ATP to be produced by mitochondria. In the case 
of uncontrolled chemical uncoupling, resistance is a function 
of the amount of uncoupler that is present. Thus, if the dosage 
is too high, all resistance is abolished resulting in maximum 
current ?oW. In the case of the presently disclosed nanotubes, 
resistance can be adjusted by changing the inner diameter of 
the nanotube and/or by “doping” the inside of the nanotubes 
With compounds of speci?c pKas. The present nanotubes act 
as proton channels Which alloW protons to How back into the 
matrix across the inner mitochondrial membrane due to the 
voltage (i.e., separation of charge) that is present. 
The How of protons can be controlled by increasing or 
decreasing the inner diameter the nanotubes such that they 
Will only alloW a How of protons only When a threshold 
voltage is reached. By decreasing the inner diameter of the 
nanotubes, the amount of voltage required to “push” protons 
through the nanotube is increased, such that only When the 
required voltage (or higher) is applied Will protons ?oW 
through the nanotubes back into the matrix. This in effect 
makes the nanotubes self-rectifying in that they Will not act as 
proton channels once the mitochondrial membrane potential 
is loWered to a set threshold. This failsafe mechanism Will 
activate regardless hoW many tubes are present, because they 
Will only act as proton channels When the threshold voltage is 
present. 
Thus, the present nanotubes are safe to administer as mito 
chondrial uncouplers, as they cause the mitochondnal uncou 
pling to stop prior to any adverse effects. 
The nanotubes, acting as proton channels, cause a reduc 
tion in mitochondrial membrane potentials, Which in turn 
increases basal metabolism, decreases reactive oxygen spe 
cies (“ROS”), and decreases detrimental loading of Ca2+ into 
mitochondria. 
The present nanotubes may be made of metals, polymers, 
semiconductors, carbons, and other materials. Preferably, the 
nanotubes are made of any elemental metal that Will plate or 
coat the Walls of the template used, including, but not limited 
to, gold, copper, platinum, nickel and silver. Most preferably, 
the nanotubes are made of gold, as gold is inert and does not 
cause any in?ammatory response in the body. 
The nanotubes can be made from polymers. These poly 
mers can be natural or synthetic and can include poly(vinyl 
alcohol), poly(esters), polyglycolide, polycaprolactone, poly 
(ethylene oxide), poly(butylene terephthalate), poly(hy 
droxyalkanoates), hydrogels, modi?ed poly(saccharide)s 
such as starch, cellulose, and chitosan. 
Different characteristics of the nanotubes, such as the 
effective half-life (i.e., hoW long the nanotube Will be stable in 
the body), can be altered by changing the percent composition 
of the different polymers to achieve a desired effect. See 
Martin C. R., et al., Materials science: Expanding the 
Molecular Electronics Toolbox, Science, 2005 July 1, 309 
(5731):67-8; Kohli, P., et al., Smart Nanotubesfor Biotech 
nology, CurrentPharmaceutical Biotechnology, 2005 Febru 
ary, 6(1):35-47; Martin C. R., Nanomaterials: A Membrane 
Based Synthetic Approach, Science (1994), 266, 1961 -1 966; 
and Martin C. R., The Emerging Field ofNanotube Biotech 
nology, Nature RevieWs Drug Discoveries (2003), 2 29-37. 
Copolymers of poly(ester)s based on polylactide, polygly 
colide, and polycaprolactone can also be used to make the 
nanotubes. Multiblock copolymers of poly(ethylene oxide) 
and poly(butylene terephthalate) can also be used to make the 
nanotubes. The poly(esters) can be based on polylactide. 
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The use of nanotubes as proton channels in mitochondria 
can circumvent the toxic side effects of chemical uncouplers 
and safely increase metabolism (and promote Weight loss). 
Nanotubes act as high-conductance proton channels, mim 
icking chemical uncouplers, Without substantially any chance 
of toxicity. This can be accomplished by the use and manu 
facturing of voltage-dependent nanotubes that act as effective 
proton diodes and recti?ers in the mitochondrial membrane. 
The nanotubes can conduct protons only When a speci?c 
potential (i.e., breakover voltage) is reached Which causes the 
nanotubes to act as proton channels Which Will reduce mito 
chondrial membrane potential to a point that Will close the 
nanotube proton channel. 
As discussed supra, one reason that the present nanotubes 
are safe for use in the body is the mechanism of conducting 
protons only When a speci?c potential (i.e., breakover volt 
age) is reached. This characteristic of the nanotubes causes a 
drop in the mitochondrial membrane potential that closes the 
nanotube proton channel, in effect making the nanotubes 
self-rectifying. Therefore, nanotubes can be designed to 
maintain a speci?c mitochondrial membrane potential that 
can signi?cantly increase metabolism, substantially Without 
the possibility of toxicity, because the nanotubes can be 
designed to not function at a mitochondrial membrane poten 
tial beloW the threshold for ATP production. Additionally, the 
nanotubes (i.e., proton channels) can only function in the 
mitochondria, because a proton gradient of about 120-220 
mV does not exist anyWhere else in mammalian cells. 
Nanotubes can be designed to maintain a speci?c mito 
chondrial membrane potential that can signi?cantly increase 
metabolism Without the toxicity associated With reducing 
mitochondrial membrane potential beloW the threshold for 
ATP production. Nanotube proton channels can function only 
at the mitochondria in the cells of in an individual because a 
proton gradient of similar magnitude does not exist anyWhere 
else in an individual’s cell. 
The inner diameter (“id”) of the nanotubes can be altered 
until the desired conductance is realiZed. It is Well knoWn that 
reducing the nanotube i.d. also reduces the conductance (in 
creases the resistance) of the channel to proton How in accor 
dance With Ohms laW. See NishiZaWa M., et al., Metal Nano 
tubule Membranes with Electrochemically Switchable [on 
Transport Selectivity, Science (1995), 268, 700-702; Miller 
S. A., et al., Electroosmotic ?ow in template-prepared carbon 
nanotube membranes, J.Am. Chem. Soc (2001). 123, 12335 
12342; and Martin, C. R., Nanomaterials: A Membrane 
Based Synthetic Approach, Science (1994), 266, 1961-1966. 
Further, the proton conductance and selectivity of the 
nanotubes can be adjusted and/or increased by using com 
pounds of speci?c pKa including speci?c chemisorbed amino 
acids. These amino acids can be incorporated into the inner 
Walls of the nanotubes during template synthesis. Depending 
on the chemical properties of the amino acids, nanotubes that 
are highly-selective for protons in addition to being pH sen 
sitive can be created. 
Generally, a pH difference of about 0.5 exists across the 
inner mitochondrial membrane. When the interior surface of 
the nanotubes is coated (i.e., “doped”) With compounds of 
speci?c pKa such that the nanotube shuts off When this pH 
gradient reaches a certain level such that the compound Will 
no longer be protonated and cease to conduct protons. This 
acts as a second failsafe device, in addition to controlling 
proton conductance. Based on the pH gradient across the 
mitochondrial inner membrane, any compound With a pKa in 
the range of4 to 5 (in H2O at ~37° C.) and that has a small 
enough molecular Weight that it can ?t into the nanotube, 
Would be ideal for this application. lon selectivity can also be 
US 7,919,699 B2 
adjusted by doping the inside of the nanotubes With com 
pounds of the opposite charge of the ion selected. 
Preparation of Nanotubes 
A template method of forming the nanotubes generally 
includes (a) immersing a template membrane into methanol, 
(b) immersing the template membrane into a solution having 
SnCl2 and tri?uoroacetic acid, (c) immersing the template 
membrane in methanol tWice, (d) immersing the template 
membrane in an aqueous ammonical AgNO3 solution or any 
aqueous solution containing the material you Wish to use for 
plating of the membrane, (e) immersing the template mem 
brane in methanol, (f) placing the template membrane in a 
gold-plating bath, the gold-plating bath having commercial 
gold plating solution, (g) adjusting the pH of the gold-plating 
bath to about 10 by drop-Wise addition of HZSO4 While stir 
ring, (h) placing the template membrane in the gold-plating 
bath for different periods of time to obtain holloW tube-like 
structures of different inside diameters. CH2Cl2 is added to 
dissolve the membrane. 
In one embodiment, the template method of forming the 
nanotubes includes (a) immersing a template membrane into 
methanol for about 2-10 minutes, (b) immersing the template 
membrane into a solution having SnCl2 and tri?uoroacetic 
acid for about 30-60 minutes, (c) immersing the template 
membrane in methanol tWice for about 1-5 minutes each time, 
(d) immersing the template membrane in an aqueous 
ammonical AgNO3 solution for about 2-10 minutes, (e) 
immersing the template membrane in methanol for about 
2-10 minutes, (f) placing the template membrane in a gold 
plating bath at a temperature of about 2-100 C., the gold 
plating bath having commercial gold plating solution, Which 
typically includes Na2SO3, formaldehyde, and NaHCO3, (g) 
adjusting the pH of the gold-plating bath to about 10 by 
drop-Wise addition of H2SO4 While stirring, (h) placing the 
template membranes in the gold-plating bath for different 
periods of time to obtain holloW tube-like structures of dif 
ferent inside diameters. CH2Cl2 is added to dissolve the mem 
brane. 
Preferably, in another embodiment, the template method of 
forming the nanotubes includes (a) immersing a template 
membrane into methanol for about 2-10 minutes, preferably 
for about 5 minutes, (b) immersing the template membrane 
into a solution having about 0.025 M SnCl2 and 0.07 M 
tri?uoroacetic acid for about 30-60 minutes, preferably for 
about 45 minutes, (c) immersing the template membrane in 
methanol tWice for about 1-5 minutes each time, preferably 
for about 2.5 minutes each time, (d) immersing the template 
membrane in a 0.029 M aqueous ammonical AgNO3 solution 
for about 2-10 minutes, preferably for about 5 minutes, (e) 
immersing the template membrane in methanol for about 
2-10 minutes, preferably for about 5 minutes, (f) placing the 
template membrane in a gold-plating bath at a temperature of 
about 2-100 C., preferably at a temperature of 50 C., the 
gold-plating bath having commercial gold plating solution, 
Which typically includes 0.127 M Na2SO3, 0.625 M formal 
dehyde, and 0.025 M NaHCO3, (g) adjusting the pH of the 
gold-plating bath to about 10 by drop-Wise addition of 0.5 M 
H2SO4 While stirring, (h) placing the template membranes in 
the gold-plating bath for different periods of time to obtain 
holloW tube-like structures of different inside diameters. 
CH2Cl2 is added to dissolve the membrane. 
In another embodiment, a polycarbonate track etched 
membrane (e.g., from SterlitechTM Corporation) is immersed 
in methanol for 5 minutes. Substantially all of the methanol is 
drained off and the membrane is immersed in a solution 
Which is about 0.025 M SnCl2 and about 0.07 M tri?uoroace 
tic acid. Both the chemicals should be added in equal vol 
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umes. The membrane is kept in the SnCl2 and tri?uoroacetic 
acid solution for about 30-60 minutes. The solution is then 
drained off and the membrane is immersed in methanol. The 
immersion of the membrane in methanol is to remove any 
residual SnCl2 or tri?uoroacetic acid. The membrane is then 
immersed in an aqueous ammonical AgNO3 solution. The 
membrane is placed in a solution containing substantially 
equal volumes of Na2SO3, NaHCO3, HCOOH, and a com 
mercial gold plating solution. The solution should be main 
tained at a temperature of about 5 ° C. The membranes are kept 
in the gold-plating solution for 3, 6, 9 or 24 hours. The inner 
diameter of the tubes changes With the plating time. After the 
respective amount of time, the solution is drained-off and 
CH2Cl2 or other similar solvent is added to dissolve the mem 
brane. The solution is then centrifuged to separate aggregated 
nanotubes. The solution is then removed leaving the aggre 
gated nanotubes behind. PEG is added to the aggregated 
nanotubes such that the PEG coats the nanotubes causing the 
aggregated nanotubes to separate such that substantially indi 
vidual nanotubes coated With PEG are available in Water or 
similar solvent as a solution. The mixture is then vortexed 
(i.e., mixed vigorously using a genie vortexer or other similar 
mixer) to aid the coating of the nanotubes With PEG thereby 
increasing the availability of the nanotubes in solution. The 
mixture is then ?ltered to remove any particulate matter. The 
?ltered nanotubes are then pelleted by centrifugation, the 
supernatant removed and the pellet re-suspended in ethanol to 
remove excess PEG. The nanotubes are thenpelleted again by 
centrifugation, the supernatant removed and the pellets are 
re-suspended in sterile Water and stored at about 40 C. 
The plated membranes obtained from the method 
described above can then be placed in a solution of histidine 
(or any compound one Wishes to us to dope the inside of the 
nanotubes). The plated membranes are left in the histidine 
solution for 24 hours to alloW the histidine to coat the inner 
Walls of the plated membranes having the nanotubes. The 
coated membranes can be removed and placed in CH2Cl2 and 
sonicated, so as to dissolve the membrane. PEG can be added 
to the resultant solution Which Will coat the outside of the 
nanotubes making them soluble. The PEG solution can be 
centrifuged so that the nanotubes settle at the bottom. The 
PEG solution can be removed so that the nanotubes can be 
collected. Ethanol (“EtOH”) can be added alloWing the tubes 
to be suspended in a sterile medium. The solution can be 
drained off after centrifuging and EtOH can be added to 
obtain histidine coated nanotubes. 
PEG is added to the outside of the nanotubes in order to 
alloW them to become soluble in solution, prior to ?ltration. 
Nanotubes that are manufactured in the absence of PEG do 
not make it through the ?ltration process. 
Further, the proton conductance of the nanotubes can be 
adjusted by using compounds of speci?c pKa including spe 
ci?c chemisorbed amino acids. These amino acids can be 
incorporated into the inner Walls of the nanotubes during 
template synthesis. Depending on the chemical properties of 
the amino acids nanotubes that are highly-selective for pro 
tons in addition to being pH sensitive can be created. Gener 
ally, a pH difference of about 0.5 exists across the inner 
mitochondrial membrane. When the interior surface of the 
nanotubes is doped With compounds of speci?c pKa, that the 
nanotubes shut off When a speci?c pH is reached. 
Any Weak acid that has a pKa of4-5 in H2O at about 370 C. 
and has molecules that can penetrate the id. of the nanotubes, 
can be used as proton conductance adjusting compounds. In a 
preferred embodiment, these proton conductance adjusting 
compounds are selected from the group consisting of aspar 
ate, glutamate, and combinations thereof. 







